Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Trading banner 1
Trading banner 2
Trading banner 3
Trading banner 4
Trading banner 5
Trading banner 6
Trading banner 7
Trading banner 8
Trading banner 9
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Vertex Pharmaceuticals Incorporated (VRTX) – Vertex Pharmaceuticals Incorporated Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Vertex Pharmaceuticals (VRTX) trades at $425.00, showing minimal daily movement. The stock exhibits strong fundamentals with a 35.51% net income margin and consistent earnings beats, though technical indicators signal a bearish short-term trend. Recent news highlights upcoming Q1 2026 earnings on May 4, 2026, with focus on Trikafta demand and new drug sales.
The outlook remains positive given robust profitability and a unanimous 'Buy' analyst consensus with a $565.00 price target, implying significant upside. Key risks include competitive threats to its cystic fibrosis franchise and potential earnings volatility. The stock's current valuation at 25.38x P/E appears reasonable for its growth profile.
Read full analysis

Key Stats

  • Market Cap
    $108.54B
  • Sector
    Health
  • 3M Drawdown
    -15.21%
  • Enterprise Value
    $103.28B
  • Dividend Yield
    -
  • Trading Activity
    49% Buy | 51% Sell
  • Typical Hold Time
    100 days
$424.33
52W Low: $366.54
08 Aug 2025
52W High: $499.17
10 Mar 2026

Vertex Pharmaceuticals Incorporated (VRTX) is currently valued at a market capitalization of $108.54B, with an enterprise value of $103.28B. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $499.17, highlighting its annual price range. Over the past three months, Vertex Pharmaceuticals Incorporated has recorded a drawdown of -15.21%, reflecting recent price volatility. On average, investors hold Vertex Pharmaceuticals Incorporated for approximately 100 days, indicating typical investor behavior on the platform.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.


Technical Indicators
|
|
|
Overall Summary
Bearish (18)Neutral (4)Bullish (5)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $108.54B
  • Sector
    Health
  • 3M Drawdown
    -15.21%
  • Enterprise Value
    $103.28B
  • Dividend Yield
    -
  • Trading Activity
    49% Buy | 51% Sell
  • Typical Hold Time
    100 days
$424.33
52W Low: $366.54
08 Aug 2025
52W High: $499.17
10 Mar 2026

Vertex Pharmaceuticals Incorporated (VRTX) is currently valued at a market capitalization of $108.54B, with an enterprise value of $103.28B. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $499.17, highlighting its annual price range. Over the past three months, Vertex Pharmaceuticals Incorporated has recorded a drawdown of -15.21%, reflecting recent price volatility. On average, investors hold Vertex Pharmaceuticals Incorporated for approximately 100 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!